Nabriva Therapeutics plc - Ordinary Shares (NBRV): Price and Financial Metrics
Nabriva Therapeutics plc - Ordinary Shares (NBRV)
Today's Latest Price: $1.28 USD
0.01 (-0.78%)
Updated Feb 28 1:02pm
Add NBRV to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
NBRV Stock Summary
- Nabriva Therapeutics plc's stock had its IPO on September 18, 2015, making it an older stock than only 14.68% of US equities in our set.
- With a price/sales ratio of 112.66, Nabriva Therapeutics plc has a higher such ratio than 97.95% of stocks in our set.
- With a year-over-year growth in debt of 4,722.68%, Nabriva Therapeutics plc's debt growth rate surpasses 98.86% of about US stocks.
- Stocks that are quantitatively similar to NBRV, based on their financial statements, market capitalization, and price volatility, are NSTG, PACB, MRAM, VUZI, and EMAN.
- NBRV's SEC filings can be seen here. And to visit Nabriva Therapeutics plc's official web site, go to www.nabriva.com.
NBRV Daily Price Range
NBRV 52-Week Price Range
NBRV Stock Price Chart More Charts
NBRV Price/Volume Stats
| Current price | $1.28 | 52-week high | $3.27 |
| Prev. close | $1.29 | 52-week low | $1.16 |
| Day low | $1.22 | Volume | 402,950 |
| Day high | $1.29 | Avg. volume | 1,268,090 |
| 50-day MA | $1.41 | Dividend yield | N/A |
| 200-day MA | $1.95 | Market Cap | 1.21B |
Nabriva Therapeutics plc - Ordinary Shares (NBRV) Company Bio
Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company was founded in 2006 and is based in Wien, Austria.
Top Stories View All
Cannabis Stocks: The Week in Review
Best & Worst Performing Stock Industries for February 27, 2020
Best & Worst Performing Small Cap Stocks for February 27, 2020
Best & Worst Performing Mid Cap Stocks for February 27, 2020
Best & Worst Performing Large Cap Stocks for February 27, 2020
View All Top Stories
Loading social stream, please wait...